Page last updated: 2024-09-05

sorafenib and CCMMT

sorafenib has been researched along with CCMMT in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Antoniou, G; Bertulli, R; Blay, JY; Brahmi, M; Casali, PG; Collini, P; Dei Tos, AP; Dufresne, A; FucĂ , G; Fumagalli, E; Gronchi, A; Grosso, F; Hindi, N; Jones, RL; Le Cesne, A; Mir, O; Provenzano, S; Sanfilippo, R; Sbaraglia, M; Stacchiotti, S1
Gao, F; Huang, C; Sun, R; Wang, H; Zhang, S; Zhang, Y1

Other Studies

2 other study(ies) available for sorafenib and CCMMT

ArticleYear
Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas).
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 09-01, Volume: 25, Issue:17

    Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Everolimus; Female; Gemcitabine; Humans; Indazoles; International Agencies; Male; Middle Aged; Perivascular Epithelioid Cell Neoplasms; Prognosis; Pyrimidines; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor Receptor-1

2019
Combination targeted therapy of VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus induced a remakable response of rapid progressive Uterine PEComa.
    Cancer biology & therapy, 2016, 06-02, Volume: 17, Issue:6

    Topics: Antineoplastic Agents; Female; Humans; Middle Aged; Niacinamide; Perivascular Epithelioid Cell Neoplasms; Phenylurea Compounds; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Uterine Neoplasms

2016